Limits...
Suppression of REV7 enhances cisplatin sensitivity in ovarian clear cell carcinoma cells.

Niimi K, Murakumo Y, Watanabe N, Kato T, Mii S, Enomoto A, Asai M, Asai N, Yamamoto E, Kajiyama H, Shibata K, Kikkawa F, Takahashi M - Cancer Sci. (2014)

Bottom Line: Enhanced immunoreactivity to REV7 was associated with poor prognosis represented by reduced progression-free survival in advanced stage (stage II-IV) EOC as assessed using Kaplan-Meier curves and log-rank tests.Knockdown of REV7 in CCC cells decreased cell proliferation without affecting cell cycle distribution.In a nude mouse tumor xenograft model, inoculated REV7-knockdown tumors showed significantly reduced tumor volumes after cisplatin treatment compared with those of the control group.

View Article: PubMed Central - PubMed

Affiliation: Department of Pathology, Nagoya University Graduate School of Medicine, Nagoya, Japan; Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Show MeSH

Related in: MedlinePlus

Knockdown of REV7 inhibits cell proliferation but does not affect the cell cycle of ovarian clear cell carcinoma cells. (a) Western blot images of REV7 expression in wild-type (WT), REV7-knockdown (shREV7), and control (shCont) clear cell carcinoma cells. The image of β-actin is indicated as an internal control. (b) Cell proliferation analysis of REV7-knockdown and control cells. The means ± SDs of relative cell counts are shown. *P < 0.05; **P < 0.01. (c) Graphical depiction of data obtained from flow cytometry analysis. Percentages of cell populations in each phase of the cell cycle are indicated.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4317831&req=5

fig02: Knockdown of REV7 inhibits cell proliferation but does not affect the cell cycle of ovarian clear cell carcinoma cells. (a) Western blot images of REV7 expression in wild-type (WT), REV7-knockdown (shREV7), and control (shCont) clear cell carcinoma cells. The image of β-actin is indicated as an internal control. (b) Cell proliferation analysis of REV7-knockdown and control cells. The means ± SDs of relative cell counts are shown. *P < 0.05; **P < 0.01. (c) Graphical depiction of data obtained from flow cytometry analysis. Percentages of cell populations in each phase of the cell cycle are indicated.

Mentions: As it was revealed that REV7 is strongly expressed in CCC, we investigated the significance of REV7 expression in CCC biology. REV7-knockdown cells were generated using three CCC cell lines, ES-2, KOC-7C, and TOV-21G, by RNAi technology (Data S1). Expression levels of REV7 in the three CCC cell lines were similar and were upregulated compared with other cell lines derived from yolk sac tumor and serous adenocarcinoma (Fig. S2). Expression of REV7 was significantly suppressed in all CCC cell lines with shRNA targeting REV7 (Fig.2a). Then, we assessed the effects of REV7 knockdown on cell proliferation, in which shREV7 cells grew more slowly than shCont cells, indicating that REV7 affects cell proliferation (Fig.2b). Cell cycle distribution was also analyzed in shREV7 and shCont cells by flow cytometry, but it was not affected by REV7 depletion (Fig.2c, Data S1).


Suppression of REV7 enhances cisplatin sensitivity in ovarian clear cell carcinoma cells.

Niimi K, Murakumo Y, Watanabe N, Kato T, Mii S, Enomoto A, Asai M, Asai N, Yamamoto E, Kajiyama H, Shibata K, Kikkawa F, Takahashi M - Cancer Sci. (2014)

Knockdown of REV7 inhibits cell proliferation but does not affect the cell cycle of ovarian clear cell carcinoma cells. (a) Western blot images of REV7 expression in wild-type (WT), REV7-knockdown (shREV7), and control (shCont) clear cell carcinoma cells. The image of β-actin is indicated as an internal control. (b) Cell proliferation analysis of REV7-knockdown and control cells. The means ± SDs of relative cell counts are shown. *P < 0.05; **P < 0.01. (c) Graphical depiction of data obtained from flow cytometry analysis. Percentages of cell populations in each phase of the cell cycle are indicated.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4317831&req=5

fig02: Knockdown of REV7 inhibits cell proliferation but does not affect the cell cycle of ovarian clear cell carcinoma cells. (a) Western blot images of REV7 expression in wild-type (WT), REV7-knockdown (shREV7), and control (shCont) clear cell carcinoma cells. The image of β-actin is indicated as an internal control. (b) Cell proliferation analysis of REV7-knockdown and control cells. The means ± SDs of relative cell counts are shown. *P < 0.05; **P < 0.01. (c) Graphical depiction of data obtained from flow cytometry analysis. Percentages of cell populations in each phase of the cell cycle are indicated.
Mentions: As it was revealed that REV7 is strongly expressed in CCC, we investigated the significance of REV7 expression in CCC biology. REV7-knockdown cells were generated using three CCC cell lines, ES-2, KOC-7C, and TOV-21G, by RNAi technology (Data S1). Expression levels of REV7 in the three CCC cell lines were similar and were upregulated compared with other cell lines derived from yolk sac tumor and serous adenocarcinoma (Fig. S2). Expression of REV7 was significantly suppressed in all CCC cell lines with shRNA targeting REV7 (Fig.2a). Then, we assessed the effects of REV7 knockdown on cell proliferation, in which shREV7 cells grew more slowly than shCont cells, indicating that REV7 affects cell proliferation (Fig.2b). Cell cycle distribution was also analyzed in shREV7 and shCont cells by flow cytometry, but it was not affected by REV7 depletion (Fig.2c, Data S1).

Bottom Line: Enhanced immunoreactivity to REV7 was associated with poor prognosis represented by reduced progression-free survival in advanced stage (stage II-IV) EOC as assessed using Kaplan-Meier curves and log-rank tests.Knockdown of REV7 in CCC cells decreased cell proliferation without affecting cell cycle distribution.In a nude mouse tumor xenograft model, inoculated REV7-knockdown tumors showed significantly reduced tumor volumes after cisplatin treatment compared with those of the control group.

View Article: PubMed Central - PubMed

Affiliation: Department of Pathology, Nagoya University Graduate School of Medicine, Nagoya, Japan; Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Show MeSH
Related in: MedlinePlus